REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 AAN 2017: There is a growing body of data on the use of disease-modifying therapies in patients with progressive multiple sclerosis. The following is a summary of key studies presented at AAN 2017. Read More

REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 – The following summarizes data from key studies presented at the American Academy of Neurology annual meeting on the long-term use of disease-modifying therapies in multiple sclerosis. Read More

The U.S. Food and Drug Administration has approved ocrelizumab (Ocrevus) for the treatment of adult patients with relapsing forms of multiple sclerosis, and for primary-progressive MS. Ocrelizumab is a humanized monoclonal antibody that targets CD20+ B cells. It is the first disease-modifying therapy to be approved for PPMS. The FDA had given ocrelizumab breakthrough therapy and fast track designations, and granted it a priority review. Read More

Neurologists are a conservative group when it comes to patients contacting them by personal cell phone/email, and a majority think a social media relationship with a patient is inappropriate, according to the results of two online surveys of NeuroSens subscribers conducted by Dr. Jiwon Oh and colleagues at the University of Toronto. The results were presented at ACTRIMS Forum 2017 in Orlando, Florida in February 2017. Read More